长春瑞滨联合顺铂和依托泊甙治疗31例晚期非小细胞肺癌  

The Combination of Vinorelbine,Cisplatin and Etoposide in The Treatment for 31 Cases with Advanced Non-small Cell Lung Cancer

作　　者：李毅刚[1] 赖淑贞[1] 曾庆祉[1] 张国平[1] 

机构地区：[1]广东粤北人民医院,广东韶关512026

出　　处：《肿瘤学杂志》2003年第6期359-360,共2页Journal of Chinese Oncology

摘　　要：[目的]观察长春瑞滨联合顺铂和依托泊甙治疗晚期非小细胞肺癌的临床疗效和毒副作用。[方法]可评价的晚期非小细胞肺癌31例,均以NVB25mg/m2静注,第1,8天;DDP20mg/m2静注,第1～5天;Vp鄄16胶囊50mgBid×10天。[结果]初治17例有效率52.9%,复治14例有效率35.7%,总有效率45.2%,主要毒副反应为骨髓抑制。[结论]长春瑞滨、顺铂和依托泊甙联合化疗治疗晚期非小细胞肺癌疗效较高,副反应可耐受,值得临床进一步观察。To evaluate the efficacy and toxicity of the combination regimen of vinorelbine, cisplatin and etoposide for advanced non-small cell lung cancer.Thirty-one patients with advanced non-small cell lung cancer were enrolled in this s tudy.All of them had stageⅢ~Ⅳdisease(17of them were previously un-treated).Th e patients received NVB25mg/m 2 iv d1,8,DDP20mg/m 2 iv d1~5and Vp-1650mg po Bid for10days.The response rate was52.9%in previously untreated group and35.7%in previously treated group.The overall resp onse rate was45.2%.The main toxicity was myelosuppression.[Conclusions]The combi na-tion of vinorelbine,cisplatin and etoposide is an effective and safe regimen for advanced non-small cell lung can-cer.The toxicity is tolerable.

关 键 词：长春瑞滨 非小细胞肺癌 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]